Analysts predict that Agenus Inc (NASDAQ:AGEN) will post earnings of ($0.33) per share for the current quarter, according to Zacks. Two analysts have made estimates for Agenus’ earnings. The highest EPS estimate is ($0.28) and the lowest is ($0.38). Agenus reported earnings per share of ($0.24) during the same quarter last year, which suggests a negative year over year growth rate of 37.5%. The company is expected to issue its next quarterly earnings report on Thursday, August 8th.
On average, analysts expect that Agenus will report full-year earnings of ($0.91) per share for the current year, with EPS estimates ranging from ($1.02) to ($0.79). For the next financial year, analysts expect that the company will post earnings of ($1.29) per share, with EPS estimates ranging from ($1.58) to ($0.84). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover Agenus.
Agenus (NASDAQ:AGEN) last released its earnings results on Thursday, May 9th. The biotechnology company reported $0.12 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.42. The firm had revenue of $8.61 million during the quarter, compared to analysts’ expectations of $9.03 million.
Several institutional investors have recently bought and sold shares of the business. Rhumbline Advisers lifted its position in shares of Agenus by 5.4% in the first quarter. Rhumbline Advisers now owns 118,079 shares of the biotechnology company’s stock valued at $351,000 after acquiring an additional 6,064 shares in the last quarter. Legal & General Group Plc lifted its position in shares of Agenus by 47.7% in the fourth quarter. Legal & General Group Plc now owns 21,674 shares of the biotechnology company’s stock valued at $52,000 after acquiring an additional 7,002 shares in the last quarter. Amalgamated Bank purchased a new position in shares of Agenus in the fourth quarter valued at about $30,000. Two Sigma Securities LLC purchased a new position in shares of Agenus in the fourth quarter valued at about $31,000. Finally, BNP Paribas Arbitrage SA lifted its position in shares of Agenus by 80,579.2% in the first quarter. BNP Paribas Arbitrage SA now owns 19,363 shares of the biotechnology company’s stock valued at $58,000 after acquiring an additional 19,339 shares in the last quarter. 33.08% of the stock is owned by institutional investors and hedge funds.
AGEN stock traded up $0.02 on Thursday, reaching $2.56. 26,083 shares of the company traded hands, compared to its average volume of 1,207,908. Agenus has a one year low of $1.54 and a one year high of $3.88. The company has a market cap of $361.16 million, a P/E ratio of -1.78 and a beta of 1.86. The firm’s fifty day simple moving average is $2.78.
Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.
Featured Article: Management Fee
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.